Tissuemed’s CEO David Mandley was in China last week at the Chinese Neurosurgical Society annual congress.
Of the 12000 practicing neurosurgeons in the country (yes it’s true), around 3000 attended the congress in Lanzhou, the capital and largest city of Gansu Province in Northwest China.
The surgeons with whom David talked were extremely positive about TissuePatch technology and where it fits into their practice. While the concept of using a sealant film to reinforce dural closure against CSF leakage is entirely new to China, the concept was well understood and many surgeons said they were looking forward to using the product.
Tissuemed’s Chinese partner also enthused; “This was a very interesting show for us with a significant amount of interest in the innovative products we present. Especially it was an excellent opportunity to showcase TissuePatch so soon after CFDA approval.”